Emergent BioSolutions (EBS) Revenue (2011 - 2026)

Emergent BioSolutions has reported Revenue for 16 years, with the latest figure at $234.3 million in Q2 2026.

• On a quarterly basis, Revenue rose 66.29% year-over-year to $234.3 million in Q2 2026; TTM through Jun 2026 was $770.2 million, a 9.56% decrease from a year earlier, with the FY2025 full-year figure at $742.9 million, down 28.81% from the prior year.
• Revenue was $234.3 million for Q2 2026 at Emergent BioSolutions, up from $156.1 million in the prior quarter.
• The five-year high for Revenue was $337.9 million in Q2 2023, with the low at $140.9 million in Q2 2025.
• Average Revenue over 5 years is $241.3 million, with a median of $241.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Revenue plunged 54.95% in 2022, then soared 82.84% in 2024.
• Over 5 years, Revenue stood at $330.2 million in 2022, then slipped by 16.23% to $276.6 million in 2023, then dropped by 29.61% to $194.7 million in 2024, then decreased by 23.63% to $148.7 million in 2025, then jumped by 57.57% to $234.3 million in 2026.
• The last three Revenue figures came in at $234.3 million (Q2 2026), $156.1 million (Q1 2026), and $148.7 million (Q4 2025), per Business Quant data.